Jounce Executing on LILRB2 Program
Insights - Jounce (JNCE) announced 2Q results today and the company is progressing well on their Phase 1 JTX-8064 (LILRB2 / ILT4) in solid tumors. Jounce completed enrollment of … Continue Reading
Premium: Read NowInsights
Impact of Delta Variant Being Overanalyzed
Insights - The Covid delta variant is making waves, and several countries are voicing concern. Below we look at the data and determine if the high alert … Continue Reading
Premium: Read Now
FDA Places Magenta’s ADC Conditioning Program On Hold
Insights - Magenta announced that the FDA has placed a clinical hold on their IND filed in June 2021 for conditioning agent MGTA-117. As a result, MGTA will need … Continue Reading
Premium: Read Now
Eloxx To Present CF Data in Early Q4 2021
Insights - Yesterday, Eloxx (ELOX) was down 17% to $1.60 after the company provided an enrolment update for ELX-02 Phase 2 in cystic fibrosis. The company expects to present … Continue Reading
Premium: Read Now
Genentech Discontinues Affimed’s BCMA Candidate
Insights - Affimed had the Q1 business update call this morning. The call was not well received after the company did not shed much light on AFM24 progress and … Continue Reading
Premium: Read NowJounce R&D Day 2021 Focuses on LILRB Family
Insights - Last week, Jounce hosted their R&D day to update investors on their pipeline and future prospects (watch webinar here). Overall, we thought the company provided good … Continue Reading
Premium: Read NowJounce Hands Over CCR8 Clinical Development To Gilead
Insights - Earlier this week Jounce (JNCE) received a $25M milestone payment from Gilead (GILD) for advancing their anti-CCR8 antibody through IND clearance. Gilead will now develop this program, … Continue Reading
Premium: Read Now